MaxCyte (NASDAQ:MXCT – Get Rating) is one of 40 publicly-traded companies in the “Commercial physical research” industry, but how does it contrast to its competitors? We will compare MaxCyte to similar businesses based on the strength of its earnings, valuation, dividends, risk, institutional ownership, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of […]
MaxCyte (NASDAQ:MXCT – Get Rating) is one of 39 public companies in the “Commercial physical research” industry, but how does it weigh in compared to its peers? We will compare MaxCyte to related companies based on the strength of its analyst recommendations, earnings, dividends, institutional ownership, profitability, valuation and risk. Analyst Ratings This is a […]
MaxCyte (NASDAQ:MXCT – Get Rating) is one of 39 publicly-traded companies in the “Commercial physical research” industry, but how does it contrast to its rivals? We will compare MaxCyte to similar companies based on the strength of its valuation, institutional ownership, dividends, profitability, risk, earnings and analyst recommendations. Institutional & Insider Ownership 65.9% of MaxCyte […]
MaxCyte (NASDAQ:MXCT – Get Rating) is one of 39 publicly-traded companies in the “Commercial physical research” industry, but how does it contrast to its peers? We will compare MaxCyte to related companies based on the strength of its risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability. Valuation & Earnings This table compares MaxCyte […]
Shares of OncoCyte Co. (NYSEAMERICAN:OCX – Get Rating) have been given an average rating of “Buy” by the six analysts that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target […]